Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens by Valkengoed, I.G.M. van et al.
Original
article
Cost eVectiveness analysis of a population based
screening programme for asymptomatic
Chlamydia trachomatis infections in women by
means of home obtained urine specimens
Irene G M van Valkengoed, Maarten J Postma, Servaas A Morré, Adriaan J C van den
Brule, Chris J L M Meijer, Lex M Bouter, A Joan P Boeke
Objectives: To evaluate the cost eVectiveness of a systematic screening programme for asymp-
tomatic Chlamydia trachomatis infections in a female inner city population. To determine the sen-
sitivity of the cost eVectiveness analysis to variation in the probability of developing sequelae.
Methods: A decision tree was constructed to evaluate health eVects of the programme, such as
averted sequelae of chlamydial infection. Cost eVectiveness from a societal perspective was esti-
mated for screening by means of a ligase chain reaction on mailed, home obtained urine
specimens, in a population with a C trachomatis test prevalence of 2.9%. An extensive sensitivity
analysis was performed for the probability of sequelae, the percentage of preventable pelvic
inflammatory disease (PID), and the discount rate.
Results:The estimated net cost of curing one woman, aged 15–40 years, of a C trachomatis infec-
tion is US$1210. To prevent one major outcome (PID, tubal factor infertility, ectopic pregnancy,
chronic pelvic pain, or neonatal pneumonia), 479 women would have to be screened. The net cost
of preventing one major outcome is $15 800. Changing the probability of PID after chlamydial
infection from 5% to 25% decreases the net cost per major outcome averted from $28 300 to
$6380, a reduction of 78%. Results were less sensitive to variations in estimates for other seque-
lae. The breakeven prevalence of the programme ranges from 6.4% for the scenario with all
probabilities for complications set at the maximum value to a prevalence of 100% for probabili-
ties set at the minimum value.
Conclusions: Systematic screening of all women aged 15–40 years for asymptomatic C tracho-
matis infections is not cost eVective. Although the results of the analyses are sensitive to variation
in the assumptions, the costs exceed the benefits, even in the most optimistic scenario.
(Sex Transm Inf 2001;77:276–282)
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Introduction
Genital infections caused by the bacteria
Chlamydia trachomatis are the most common
sexually transmitted infections in industrialised
countries. In women, C trachomatis can cause
urethritis, cervicitis, pelvic inflammatory dis-
ease (PID) and, at a later stage, tubal factor
infertility (TFI), ectopic pregnancy (EP), and
chronic pelvic pain (CPP).1 2 When giving
birth an infected woman can pass the infection
on to her child, who can develop a neonatal
conjunctivitis or pneumonia as a result of the
infection.3
Since genital chlamydial infection causes no
or few symptoms, many infections remain
undetected. Delayed treatment increases the
risk of sequelae and transmission to sex
partners. Screening is therefore indicated to
prevent the spread of C trachomatis and also to
prevent complications. Research in the United
States and Sweden has shown that the
detection and treatment of asymptomatic
infections in women results in a reduction of
complications.4 5
Cost is an important factor, which should be
taken into consideration before a screening
programme is implemented. Cost eVectiveness
analyses of opportunistic screening pro-
grammes, focusing on patients attending
healthcare clinics, or specific high risk groups,
have shown that screening becomes cost eVec-
tive at prevalences ranging from 2% to 6%.6–8
The introduction of sensitive DNA detection
methods to test non-invasive specimens, such
as urine, and the testing of mailed home
obtained samples makes it possible to extend
screening beyond the traditional settings.9–12
The cost eVectiveness of systematic screening
programmes in the general population has not
been evaluated.
In most cost eVectiveness studies to date the
costs of organising the screening, including
administrative costs, have not been included in
the analysis. Furthermore, although some
studies mention the imperfect specificity of the
test, no study has taken the cost of follow up of
false positive test results into account in the
analysis. So far, only one study has reported a
sensitivity analysis of risk estimates, although
estimating the probability of complications
based on the available literature leaves much
room for variation.7
This paper reports on the cost eVectiveness
of a systematic screening programme for
asymptomatic C trachomatis infections in
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women registered in general practice, based on
mailed home obtained urine specimens. The
sensitivity of the cost eVectiveness analysis to
variation in the probability of developing PID,
EP, TFI, and CPP was determined.
Methods
RECRUITMENT
A random sample of 5541 women, aged 15–40
years, was selected from the computer registers
of 16 inner city general practices in Amster-
dam. Between November 1996 and October
1997 these women were invited by their general
practitioner to participate in the screening pro-
gramme. Coded research material was sent to
the home address of potential participants.
Participants were requested to mail a first void,
first stream urine sample and a completed
questionnaire to the department of pathology
in a prestamped addressed envelope, which was
included in the material.
The study has been approved by the medical
ethics committee of the Vrije Universiteit in
Amsterdam.
DIAGNOSIS OF INFECTION
Urine samples were tested for the presence of C
trachomatis by means of the ligase chain
reaction (LCR) (Abbott Laboratories, Chi-
cago, IL, USA) in the laboratory of the depart-
ment of pathology of the University Hospital
Vrije Universiteit.9–12 Tests were performed
according to the instructions of the manufac-
turer.
The test results were reported back to the
general practitioners, who were instructed to
treat infected patients with a single dose of
1000 mg azithromycin, or erythromycin for
pregnant women (4 × 500 mg for 5 days).
CHARACTERISTICS OF PARTICIPANTS
Fifty per cent of the women who were invited
participated in the screening programme; 25%
of the participants were of non-Dutch origin.
Of all participating women, 120 had never been
sexually active. The prevalence of asympto-
matic infection, as determined by means of the
LCR on urine for women aged 15–20 years,
21–25 years, 26–30 years, 31–35 years, and
36–40 years was 2.4%, 4.4%, 2.8%, 2.5%, and
2.2%, respectively.
DECISION TREE ANALYSIS
Figure 1 is a diagram of the decision tree used
in the analysis. The sensitivity of the LCR on
urine was estimated to be 85%, and the specifi-
city 99%.9 10 The assumptions for the risk of an
untreated C trachomatis are listed in table 1.
The risk of developing sequelae if treatment
fails is assumed to equal the risk if a woman has
not been tested or treated eVectively.
As shown in figure 1 and table 1, the
probability of pregnancy wish is age specific.15
This was included in the model to estimate
how many women would develop an EP or
consult a specialist for TFI. In addition, only
women who gave birth while infected with C
trachomatis were included in calculations of the
probability of having a child with neonatal
conjunctivitis or neonatal pneumonia.15 For the
infectious period, an average of 52 weeks was
assumed.16
DIRECT COSTS
The administrative costs and the costs of the
materials sent to all women who were invited,
were taken into account in the model (table 2).
Based on the workload reported by partici-
pating practices, it was estimated that the pro-
gramme could be coordinated by two social
nurses, both working full time. The recruit-
ment costs for the programme have to be
Figure 1 Decision model for a population based screening programme for asymptomatic Chlamydia trachomatis infections in women. *Both A and B
apply for all infected women. **Pregnancy wish is taken into account.
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calculated for all women who were invited,
since the material was not only sent to partici-
pants, but to all eligible women. The cost of
recruitment is the sum of the cost of a urine
container, an envelope, and postage (approxi-
mately US$0.50). For participants, a cost of
$17.29 is included for return postage, and test
and laboratory costs. The costs of follow up of
an infected woman include the cost of one visit
to a general practitioner, pharmacotherapy
costs, and the pharmacist’s fees. Treatment
costs are also included for women with a false
positive test result, although treating these
women will not prevent any sequelae.
The cost estimates for sequelae are based on
research carried out by Postma et al.17 It was
assumed that 75% of women with symptomatic
PID are treated on an outpatient basis,18
involving two visits to a GP, medication, a test
for C trachomatis, and a test for Neisseria gonor-
rhoea. It is assumed that the remaining 25% are
treated on an inpatient basis for 9.6 days 18,
involving a diagnostic laparoscopy and medi-
cation.19
With regard to infertility, 66% of the women
were assumed to seek evaluation, 20% of whom
are evaluated in an inpatient setting.20 In vitro
fertilisation (an average of 2.11 attempts) was
assumed to occur in 23% of the infertile
women evaluated.
Chronic pelvic pain was assumed to be
treated with analgesic drugs, and with pelvic
ultrasonography and ambulatory laparoscopy
for 75% of the patients.6 Furthermore, outpa-
tient treatment was assumed to involve 10
appointments with a physician (three with a
GP, seven with a gynaecologist). The assump-
tion for inpatient care was two appointments
with a gynaecologist and hospitalisation for the
same duration as inpatient treatment of PID,
preceded by one visit to a GP. Seventy per cent
of cases of chronic pelvic pain were assumed to
be treated on an outpatient basis, and 30% on
an inpatient basis.6 Owing to lack of reliable
information surgery was not taken into consid-
eration.
Neonatal conjunctivitis was assumed to
involve tests for C trachomatis and N gonorrhoea
and medication. The assumption for outpa-
tient care for neonatal pneumonia was one visit
to a GP, two visits to a paediatrician, a test for
C trachomatis, and medication. One visit to a
GP and 13 days of intensive inpatient hospital
care was assumed for 10% of cases of neonatal
pneumonia.6 18
Deflators for the gross domestic product
(GDP) were used to recalculate all costs in
1996 prices. Costs were converted into US$ on
the basis of the GDP purchasing power parity
(1 US$ = 2.07 Dutch guilders).21 Estimated
costs of a hospital inpatient day for intensive
neonatal care are $1159.22 The costs of accom-
modation for a “normal” hospital inpatient day
were estimated at $304.23 Fees for examina-
tions and treatment were used to cost hospital
activities (data provided by the Academic Hos-
pital in Groningen). The cost of one in vitro
examination was estimated at $1423,20 and the
costing of medication was based on market
prices for standard prescriptions.24 The
weighted average GP charge for publicly and
privately insured patients is $15.51.25
INDIRECT COSTS
The indirect costs of C trachomatis infections
were estimated by applying the friction costs
approach. To calculate a value for the loss of
productivity from paid work, the average
labour costs according to age and sex were used
to approximate the net product. Based on an
analysis of the labour costs in the Netherlands,
the average gross income by age and sex were
adjusted and inflated to derive the average
labour costs applicable in the Netherlands in
1996.15 26 They were multiplied by the em-
ployed labour force participation rate, specified
according to age and sex, which yielded the net
product per capita from paid work.15 Based on
data obtained from the literature, 10 days of
productivity were estimated to be lost for each
case of treatment for PID or chronic pelvic
pain. Moreover, 21 days were estimated to be
lost for each case of inpatient treatment for
PID or chronic pelvic pain and 28 days for each
case of ectopic pregnancy.7 Assuming that an
ambulatory visit costs half a working day and
an appointment with a GP 1.5 hours, the loss
of productivity due to infertility management
(5 days, 4.5 hours for outpatient management,
4.5 days for inpatient management), and in
vitro fertilisation (4 days) was computed. Indi-
rect costs due to the loss of unpaid work were
not taken into consideration.
Table 1 Estimates and ranges used for the sensitivity analysis of the cost eVectiveness of a universal screening programme
for asymptomatic Chlamydia trachomatis infections in a female population
Variable Estimate (%) Range Domain References
Prevalence 2.9 — All women Study data
Sensitivity LCR 85 85–90 Tested women 9, 10
Specificity LCR 99 — Tested women 8, 10
Contacted for treatment 90 — Women with chlamydia Study data
Successfully treated 95 — Women with chlamydia, who receive
treatment
Study data
All PID 10 5–25 Women with undiagnosed or
unsuccessfully treated infection
4, 13
Asymptomatic of total PID 50 — All PID 14
Preventable PID 50 25–75 All PID 14
Infertility 8 4–16 All PID* 1
Ectopic pregnancy 8 4–16 All PID* 1
Chronic pelvic pain 15 10–20 All PID 2
Neonatal conjunctivitis 30 — Women with chlamydia* 3
Neonatal pneumonia 15 — Women with chlamydia* 3
*Discounted in the model by the age specific desire for pregnancy.
LCR = ligase chain reaction, PID = pelvic inflammatory disease.
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SUMMARY OF COSTS
Table 2 presents a summary of the cost
estimates. In the model, all future costs were
discounted at a rate of 3% per year.27 The cost
of complications in newborn babies and the
cost of PID were assigned to the year of infec-
tion. It was assumed that costs for chronic pel-
vic pain occur 5 years after PID.7 6 Costs for
ectopic pregnancy and infertility are assumed
to occur 10 years after C trachomatis infection
in women aged 15–19, 5 years after infection in
women aged 20–24, and 2 years after infection
in older women.
Health benefits (averted complications) were
not discounted, as has been suggested by
Parsonage and Neuberger.28 It must be noted
that discounting of health benefits is recom-
mended by others.27
SCREENING STRATEGIES
The following screening strategies were taken
into consideration: screening all women aged
15–25, as recommended by the guidelines of
the Centers for Disease Control,19 and screen-
ing all women aged 15–40. The cost eVective-
ness of a screening strategy was calculated as a
weighted average of age specific results,
weighted by the age distribution of women in
Amsterdam.
The cost eVectiveness is presented for two
denominators: a woman cured and a major
outcome averted (MOA). A cured woman is
defined as an asymptomatically infected
woman, detected by the screening programme,
who was eVectively treated for C trachomatis. A
major outcome is defined as either an episode
of PID, CPP, EP, TFI, or neonatal pneumonia.
Cost eVectiveness is presented in a baseline
analysis and in a sensitivity analysis.
SENSITIVITY ANALYSIS
Sensitivity analyses were performed for the
probability of developing a PID after asympto-
matic infection (range 5–25), the risk of
developing TFI after PID (range 4–16), prob-
ability of developing chronic pelvic pain (range
10–20) and finally the probability of developing
EP (range 4–16). The worst and best case
scenario in terms of cost versus benefit were cal-
culated by estimating the cost per major
outcome averted with all the probabilities set at
the minimum and maximum plausible values,
respectively. Moreover, sensitivity analyses were
applied to assumptions reflecting the prevent-
able percentage of PIDs (from 75% to 25%),
test sensitivity (from 85% to 90%), and discount
rate (range 0–7%). Sensitivity analysis was
limited to the net cost per MOA in the screening
programme aimed at 15–40 year old women.
No sensitivity analysis was performed for the
cost of the test, since a discount for large scale
screening was already included in the calcula-
tions of the costs of the test.
Breakeven prevalences were calculated for
screening with baseline assumptions, mini-
mum probabilities, and maximum probabili-
ties. The breakeven prevalence reflects the
prevalence where the costs of screening (US$)
equal those of averted healthcare costs.
Results
BASELINE ANALYSIS
As can be directly derived from the assump-
tions made, the probability of an infected
woman being detected by the screening and
being eVectively treated is estimated at 73%.
The overall test prevalence of 2.9%, found
among women in Amsterdam corresponds
with an estimated prevalence of 2.2%, cor-
rected for sensitivity and specificity of the test
assumed in the model. In a screening pro-
gramme aimed at women aged 15–40 years,
889 women would have to be screened to pre-
vent one major outcome. Given the current
participation rate, approximately twice this
number of women would have to be invited for
screening. The implementation of screening
for all women aged 15–40 years in Amsterdam
(n=161 065) could prevent a total of 59
episodes of PID, three TFIs, six EPs, and nine
cases of CPP, and could also prevent 13 cases
Table 2 Cost of the screening programme and direct and indirect costs associated with Chlamydia trachomatis infections
and sequelae in women (price level 1996, in US$)
Variable Direct (medical) cost Indirect cost
Coordination of the program (2 fulltime social workers,
cost per person)
48 309 per year —
Recruitment cost* (container, envelope, postage) 0.48 —
Laboratory test† (postage, materials, and labour) 17.29 —
Treatment (1000 mg azithromycin) 9.52 —
GP consultation 15.51 —
Symptomatic PID
Inpatient treatment 3 908 276
Outpatient treatment 67 132
Infertility‡
Inpatient evaluation 2 315 212
Outpatient evaluation 805 286
In vitro fertilisation‡ 1 423 188
Ectopic pregnancy‡ 2 909 847
Chronic pelvic pain‡
Inpatient treatment 3 310 456
Outpatient treatment 587 217
Neonatal conjunctivitis 39 —
Neonatal pneumonia
Inpatient treatment 16 150 —
Outpatient treatment 94 9
*For every woman invited to participate.
†For every participant.
‡Costs presented in the table are for women aged 15–25 years and are not discounted. In the model, all future costs were discounted
at a rate of 3% per year.
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of neonatal pneumonia from occurring as a
result of chlamydial infection.
The net cost per woman cured for a screen-
ing programme directed at women aged 15–40
years is $1210 per woman cured (table 3).
Limiting the programme to women aged
15–25 years reduces the net cost per woman
cured to $790. Net costs per MOA are $15 800
and $11 100, respectively.
SENSITIVITY ANALYSIS
The results of the sensitivity analyses are
presented in table 4. Changing the estimate for
the probability of developing PID after chlamy-
dial infection from 5% to 25% decreases the
cost per major outcome averted from $28 300
to $6380, a reduction of 78%. Similarly, plau-
sible ranges for the probability of ectopic preg-
nancy, infertility, and chronic pelvic pain result
in variations of 12%, 5%, and 7%, respectively.
Changing the value of the percentage of PIDs
that can be prevented by screening from 75%
to 25% results in a 63% decrease in cost per
major outcome averted. Assuming a further
technical development of tests, a test sensitivity
of 90% and a specificity of 99.9% were also
taken into consideration. Increasing the as-
sumed specificity resulted in a decrease in cost
per major outcome averted from $15 800 to
$9540, a decrease of 40%.
Finally, changing the discount rate from 0%
to 7% results in an increase of 1% in cost per
MOA.
BREAKEVEN PREVALENCE
Figure 2 shows the association between test
prevalence and net cost per MOA of the
programme aimed at women aged 15–40 years.
The breakeven prevalence in the baseline
analysis was 41.8%. The breakeven preva-
lences range from 6.4% for the best case
scenario to 100% for the worst case scenario.
The breakeven prevalence of a programme
aimed at women aged 15–25 ranges from 6.1%
to 100% in the sensitivity analysis.
As a test prevalence of 2.9% was found
among 15–40 year old women in Amsterdam,
the range of cost per MOA, reflecting the range
in probabilities, would be $1514 (maximum
probabilities) to $48 604 (minimum probabili-
ties). Similarly, at a test prevalence of 5%, the
interval for net cost per MOA would range
from $338 to $7485.
Discussion
This is the first cost eVectiveness analysis of a
systematic, universal screening programme
based on mailed home obtained urine speci-
mens in the general population. The results
show that the cost of a screening programme
for women was found to exceed the benefits in
both the baseline and the sensitivity analysis.
Screening all women aged 15–40, under base-
line assumptions, only becomes cost saving at a
test prevalence of 41.8% or more.
The overall test prevalence in the study
population was 2.9%. Cost eVectiveness for the
screening programme directed at women aged
15–40 years was estimated at $15 800 per
MOA. Restriction of the programme to women
aged 15–25 years lowers the net costs to
$11 100 per MOA. Another frequently used
outcome in cost eVectiveness analyses of
chlamydia screening is cost per PID averted.
PID constitutes 66.3% of the cost per MOA at
baseline.
Selective screening is one way of increasing
the eYciency of screening. Several authors
have suggested selective screening criteria for
various settings.7 8 29 However, suitable selec-
tion criteria could not been identified for
asymptomatic infections among the general
population in Amsterdam30; thus, currently a
comparison can only been made between a
universal screening programme and no screen-
ing at all.
Table 3 Cost eVectiveness analysis of a screening
programme for asymptomatic Chlamydia trachomatis
infections in a low prevalence female population (in US$)
Age group
(years)
Net cost per woman cured Net cost per MOA
Direct only Total Direct only Total
15–25 802 792 11 200 11 100
15–40 1220 1210 16 000 15 800
MOA = major outcome averted (either an episode of PID,
chronic pelvic pain, ectopic pregnancy, tubal factor infertility, or
neonatal pneumonia).
Table 4 Sensitivity analyses for a screening programme for women aged 15–40 years;
variations in the probability estimates for sequelae, discount rate, and test characteristics (in
US$)
Parameter Range (%)
Cost per MOA
(min)
Cost per MOA
(max)
Change
(%)
Risk PID 5–25 28 300 6 380 −78
Risk EP 4–16 16 500 14 600 −12
Risk TFI 4–16 16 100 15 300 −5
Risk CPP 10–20 16 400 15 300 −7
Preventable PID 25–75 28 300 10 400 −63
Sensitivity of the test 85–90 15 800* 15 800 0
Specificity of the test 99–99.9 15 800* 9 540 −40
Discount rate 0–7 15 800 15 900 +1
PID = pelvic inflammatory disease, EP = ectopic pregnancy, TFI = tubal factor infertility, CPP =
chronic pelvic pain, MOA = major outcome averted (either an episode of PID, CPP, EP, TFI, or
neonatal pneumonia), min = minimum probabilities, max = maximum probabilities.
*Estimate and resulting cost per MOA in the baseline analysis.
Figure 2 Breakeven prevalences for a screening
programme for asymptomatic Chlamydia trachomatis
infections in a female population: baseline assumptions,
maximum probabilities, minimum probabilities.MOA =
major outcome averted (either an episode of pelvic
inflammatory disease (PID), chronic pelvic pain, ectopic
pregnancy, tubal factor infertility, or neonatal pneumonia).
Maximum probabilities: assumption for all PID 25%, tubal
factor infertility 4%, ectopic pregnancy 4%, chronic pelvic
pain 10%.Minimum probabilities: assumption for all PID
5%, tubal factor infertility 4%, ectopic pregnancy 4%,
chronic pelvic pain 20%.
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The risk estimates for chlamydial infection,
used in the decision model, diVer from
estimates used in previous cost eVectiveness
analyses. Previous studies have used estimates
for PID and tubal factor infertility of 25–30%
and 10–12%, respectively.
However, no long term follow up studies of
asymptomatic infections in a low prevalence
population have yet been performed. Authors
have based the estimates on studies among
women with symptomatic infections, even
though asymptomatic infections are most likely
to be less virulent. In order to take that factor
into account, lower estimates were used at
baseline, and the estimates were varied over a
wide range in the sensitivity analysis.
Similarly, the risk of a silent PID should be
treated diVerently from the risk of an overt
PID. Although several studies have attempted
to study the association between silent PID and
sequelae,31 32 there is not insuYcient evidence
to quantify any association. Consequently, it
was not possible to make a distinction between
silent and overt PID in the analysis. Instead,
the baseline probability of developing sequelae
after PID was adjusted, and a sensitivity analy-
sis was performed.
The results of the sensitivity analysis under-
score the importance of valid risk estimation,
since this can have a substantial impact on the
outcome of the analysis. In this study, the cost
per MOA was extremely sensitive to variations
in the assumption reflecting the chance of
developing PID. Increasing the estimate from
5% to 25% resulted in a 78% decrease in cost
per MOA. A similar eVect was seen when the
percentage of preventable PIDs was changed
from 75% to 25%. The model was also
sensitive to the specificity of the test. No health
gains or associated averted costs can be
achieved among cases with a false positive test
result; the costs decrease by 40% if the specifi-
city of the test is estimated at 99.9% instead of
99%. Variations in the estimates for ectopic
pregnancy, tubal factor infertility, chronic
pelvic pain, test sensitivity, and discount rate
had much less impact.
COSTS CONSIDERED
All costs have been estimated for the Nether-
lands and converted into US$. Cost in the
model could reflect local diVerences in health-
care organisation and labour costs. Further-
more, the costs of health care and tests may
change over time.
In the decision tree, the cost of all materials
sent to participants and non-participants was
included. Administrative costs, such as pro-
gramme coordination, were also included. In
practice, the costs will probably be higher,
because of extra consultations for women who
are worried about the potential consequences
of the infection, the cost of media campaigns
and other activities that would accompany the
implementation of a programme. Further-
more, no physician fees for the screening were
included, although other programmes—for
example, influenza vaccination, that have been
implemented in the Netherlands have included
fees for physicians.33
In the analysis, complications of antibiotic
treatment and referral and treatment of part-
ners were not taken into consideration. In-
fected partners may reinfect females who have
been screened, and can contribute to the
spread of the infection in the population. It has
been suggested recently, that men should
always be included in a screening programme,
and not just as “partners of infected women,”34
the reason for this being that targeting women
only “stereotypes” them and aVects their sexu-
ality. Partner referral and screening aimed at
men will be taken into account in a future
evaluation of the eVects of screening over time,
using a more sophisticated dynamic model.
One hazard of cost eVectiveness analysis is
that it provides a unidimensional view of
screening. The emphasis is placed on proving
that the intervention is cost eVective although,
as this study shows, results can depend strongly
on the assumptions included in a decision
model. Moreover, other important aspects,
such as invasion of privacy, psychological and
social consequences of the test result, and the
danger of medicalisation cannot be included in
the model.
In conclusion, a universal screening pro-
gramme for asymptomatic C trachomatis infec-
tions among 15–40 year old women is not cost
eVective. Although the results of the analyses
are sensitive to variation in the assumptions,
the costs exceed the benefits even in the most
optimistic scenario.
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